Das Primäre ZNS-Lymphom (UNI-MED Science)

By Gerald Illerhaus
Primäre ZNS-Lymphome (PZNSL) sind definiert als Non-Hodgkin-Lymphome, die bei Diagnosestellung ausschließlich im Gehirnparenchym, in den Meningen und/oder im Rückenmark bzw. im vitreoretinalen Bereich lokalisiert sind. Sie treten bei immuninkompetenten Patienten sehr viel häufiger auf als bei immunkompetenten. In der Regel handelt es sich um ein aggressives, diffuses großzelliges B-Zell-Lymphom, bei dem die mediane Überlebenszeit ohne Therapie nur einige Wochen bis Monate nach Diagnose beträgt. Das therapeutische Spektrum der PZNSL wird beschränkt durch die Schwierigkeit, die Blut-Hirn-Schranke zu überwinden. Ist dies aber gegeben, ist die Chemosensitivität hoch. Aufgrund der Seltenheit dieser Tumorerkrankung basieren die meisten Studien zwar nur auf kleinen Patientenzahlen mit eingeschränkter Aussagekraft. Dennoch konnten in den letzten Jahren vielversprechende kurative Therapieansätze etabliert werden, die auf einer Induktions- und nachfolgenden Konsolidierungstherapie beruhen und hohe Remissionsraten sowie ein mehrjähriges progressionsfreies Überleben ermöglichen. All diese Aspekte sind in der vorliegenden Monographie berücksichtigt, in der das aktuelle Wissen zu den PZNSL kompakt und informativ zusammenfasst ist.

Looking for a comprehensive guide to Primäre ZNS-Lymphome (PZNSL)? Look no further than the new publication by Gerald Illerhaus, which offers a wealth of expert information on this rare form of cancer.

Non-Hodgkin-Lymphome that are only found in the brain parenchyma, the meninges, and/or the spinal cord and/or in the vitreoretinal area are defined as Primäre ZNS-Lymphome or PZNSL. This type of cancer is more commonly found in immunocompromised patients than in immunocompetent ones. Typically involving an aggressive, diffuse large B-cell lymphoma, with a median survival time of only a few weeks to months without treatment, the therapeutic options for treating PZNSL are often limited as a result of the blood-brain barrier.

However, with the ability to overcome this barrier, chemosensitivity can be high and curative treatments may be used. Despite being a rare form of cancer with fewer studies available and fewer patients to draw on, exciting new approaches have been established in recent years that have led to high remission rates and longer progression-free survival.

Throughout the book, Illerhaus presents a concise, informative summary of the current knowledge of PZNSL. This enables readers to get an in-depth look at this complex form of cancer. In addition to providing a comprehensive review of the disease, Illerhaus also offers insights into cutting-edge treatments and the latest research findings. Readers will undoubtedly come away from this book feeling well-informed, and they will be empowered to continue learning and understanding PZNSL.

One aspect of the book that stands out is the way that it balances scientific insights with understandable language. This makes it a great choice for both professionals dealing with the disease and patients and their families who want to understand it. Readers will appreciate the detailed explanations of the medical terms used throughout the book, and the thorough descriptions of the various PZNSL treatments available will leave them feeling well-informed.

The book also includes a variety of charts, tables, and illustrations, all of which help to break down complex information into easily digestible chunks. The end result is a highly readable, engaging, and accessible guide to a complex form of cancer.

If you are interested in understanding more about PZNSL, whether as a medical practitioner or someone living with the disease, this book is an excellent choice. Order your copy today and discover the latest insights into PZNSL treatment and research.

Product Details

• Publisher ‏ : ‎ UNI-MED; 1st edition (30 Nov. 2019)
• Language ‏ : ‎ German
• Hardcover ‏ : ‎ 77 pages
• ISBN-10 ‏ : ‎ 3837424022
• ISBN-13 ‏ : ‎ 978-3837424027